These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 27894229)

  • 1. [Self-reported experience in patients treated with Hepatitis C direct acting antivirals].
    Cañamares Orbis I; Saez de la Fuente J; Izquierdo García E; Esteban Alba C; Such Díaz A; Escobar Rodríguez I
    Farm Hosp; 2016 Nov; 40(n06):569-578. PubMed ID: 27894229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study.
    Sundberg I; Lannergård A; Ramklint M; Cunningham JL
    BMC Psychiatry; 2018 May; 18(1):157. PubMed ID: 29843679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and acceptability of adherence support for direct acting antiviral therapy for hepatitis C in a low-threshold primary health-care opioid agonist treatment program.
    Chronister KJ; Lothian R; Gilliver R; Kearley J; Read P
    Drug Alcohol Rev; 2019 Feb; 38(2):185-189. PubMed ID: 30761640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of a pharmaceutical care program for patients with hepatitis C treated with new direct-action antivirals.
    Campos Fernández de Sevilla MÁ; Gallego Úbeda M; Heredia Benito M; García-Cabrera E; Monje García B; Tovar Pozo M; Delgado Téllez de Cepeda L; Iglesias-Peinado I
    Int J Clin Pharm; 2019 Apr; 41(2):488-495. PubMed ID: 31028599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measure of adherence to direct-acting antivirals as a predictor of the effectiveness of hepatitis C treatment.
    Campos Fernández de Sevilla MÁ; Gallego Úbeda M; Tovar Pozo M; García-Cabrera E; Monje García B; Tutau Gómez F; Delgado Téllez de Cepeda L; Iglesias-Peinado I
    Int J Clin Pharm; 2019 Dec; 41(6):1545-1554. PubMed ID: 31650508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
    Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
    J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt.
    Youssef NF; El Kassas M; Farag A; Shepherd A
    BMC Gastroenterol; 2017 Jan; 17(1):18. PubMed ID: 28109264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy.
    Rodis JL; Kibbe P
    Gastroenterol Nurs; 2010; 33(5):368-73. PubMed ID: 20890160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population.
    Juanbeltz R; Castilla J; Martínez-Baz I; O'Leary A; Sarobe M; San Miguel R
    Qual Life Res; 2019 Jun; 28(6):1477-1484. PubMed ID: 30666549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of health status in patients with hepatitis c treated with and without interferon.
    Ragusa R; Bertino G; Bruno A; Frazzetto E; Cicciu F; Giorgianni G; Lupo L
    Health Qual Life Outcomes; 2018 Jan; 16(1):17. PubMed ID: 29343250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct-acting antivirals: The GRUviC project.
    Chamorro-de-Vega E; Rodriguez-Gonzalez CG; Gimenez-Manzorro A; de Lorenzo-Pinto A; Iglesias-Peinado I; Herranz A; Sanjurjo M;
    Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28836363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients.
    Yaya I; Roux P; Marcellin F; Wittkop L; Esterle L; Spire B; Dominguez S; Elegbe BA; Piroth L; Sogni P; Salmon-Ceron D; Carrieri MP;
    PLoS One; 2018; 13(7):e0199874. PubMed ID: 29975764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients.
    Juanbeltz R; Martínez-Baz I; San Miguel R; Goñi-Esarte S; Cabasés JM; Castilla J
    PLoS One; 2018; 13(10):e0205277. PubMed ID: 30300395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience.
    Elsharkawy A; El-Raziky M; El-Akel W; El-Saeed K; Eletreby R; Hassany M; El-Sayed MH; Kabil K; Ismail SA; El-Serafy M; Abdelaziz AO; Shaker MK; Yosry A; Doss W; El-Shazly Y; Esmat G; Waked I
    J Hepatol; 2018 Apr; 68(4):691-698. PubMed ID: 29223371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacist engagement within a hepatitis C ambulatory care clinic in the era of a treatment revolution.
    Gauthier TP; Moreira E; Chan C; Cabrera A; Toro M; Carrasquillo MZ; Corentin M; Sherman EM
    J Am Pharm Assoc (2003); 2016; 56(6):670-676. PubMed ID: 27667501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value and innovation of direct-acting antivirals: long-term health outcomes of the strategic plan for the management of hepatitis C in Spain.
    Turnes J; Domínguez-Hernández R; Casado MÁ
    Rev Esp Enferm Dig; 2017 Dec; 109(12):809-817. PubMed ID: 29152988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness of therapeutic patient education on adherence to oral anti-cancer medicines in adult cancer patients in ambulatory care settings: a systematic review.
    Arthurs G; Simpson J; Brown A; Kyaw O; Shyrier S; Concert CM
    JBI Database System Rev Implement Rep; 2015 Jun; 13(5):244-92. PubMed ID: 26455611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis.
    Hill LA; Delmonte RJ; Andrews B; Richards L; Soto R; Collier S; Kuo A; Cachay E
    Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1378-1383. PubMed ID: 29975243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profile and predictors of health related quality of life among type II diabetes mellitus patients in Quetta city, Pakistan.
    Iqbal Q; Ul Haq N; Bashir S; Bashaar M
    Health Qual Life Outcomes; 2017 Jul; 15(1):142. PubMed ID: 28709437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
    Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
    Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.